Did Changes to Adult Hearing Aid Pathways Due to COVID-19 Affect Patient Outcomes? A Service Evaluation.


Journal

American journal of audiology
ISSN: 1558-9137
Titre abrégé: Am J Audiol
Pays: United States
ID NLM: 9114917

Informations de publication

Date de publication:
21 Sep 2022
Historique:
pubmed: 15 9 2022
medline: 24 9 2022
entrez: 14 9 2022
Statut: ppublish

Résumé

The objective of this study was to determine whether changes to adult hearing aid provision during COVID-19 affected patient outcomes or service efficiency. A service evaluation compared three cohorts: patients who had hearing aid provision prior to the COVID-19 pandemic (the conventional pathway); patients who had hearing aid provision during the initial national lockdown (remote fittings); and patients who had hearing aid provision during the gradual reopening phase (a blended service with both face-to-face and remote service provision). Outcomes measured the effectiveness and efficiency of the service, using the Glasgow Hearing Aid Benefit/Difference Profiles (GHABP/DP) and number of follow-up appointments required. Results were assessed using descriptive statistics and error bars, separately for new and existing users. This study included 240 hearing aid users. Remote fittings adversely impacted the effectiveness of provision for new hearing aid users with a reduction in all GHABP domains. While new users' benefit was equally as good for blended and conventional service provision, blended provision was less efficient and required more follow-up visits. For existing hearing aid users, no differences were seen in GHADP outcomes of different pathways and remote fittings increased service efficiency. Remote hearing aid fittings are less effective for new users than hearing aids fitted using standard face-to-face service provision or service provision using a blended model of remote and face-to-face care. Current pathways using a blended model of care are less efficient but equally effective for new hearing aid users compared with provision prior to COVID-19 and result in equivalent patient outcomes in terms of benefit. https://doi.org/10.23641/asha.21067585.

Identifiants

pubmed: 36103809
doi: 10.1044/2022_AJA-21-00195
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

876-891

Auteurs

Zoe Duckworth (Z)

Manchester Centre for Audiology and Deafness, School of Healthcare Science, The University of Manchester, United Kingdom.
University Hospitals Plymouth NHS Trust, United Kingdom.

Adam Beckman (A)

University Hospitals Plymouth NHS Trust, United Kingdom.

Antje Heinrich (A)

Manchester Centre for Audiology and Deafness, School of Healthcare Science, The University of Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH